J&J Tremfya Shows Consistent Results In Crohn's Disease
Hits 28% Fistula Remission Vs 10% In Placebo
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease
Johnson & Johnson disclosed new Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas. Results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting. TREMFYA delivered consistent fistula remission outcomes across difficult-to-treat groups, includi